An Act to amend 94.55 (1); to create 94.55 (5) of the statutes; Relating to: regulating hemp-derived cannabinoid products.
Impact
The bill’s provisions will directly affect the sale and distribution of hemp-derived products statewide by imposing age restrictions and requiring detailed product testing and labeling. For instance, underage individuals are prohibited from purchasing hemp-derived cannabinoid products, and sellers must ensure that their products are accompanied by a certificate of analysis from an accredited laboratory. This analysis must certify that the cannabinoid content matches what is labeled and that the products are free from harmful contaminants. Furthermore, products are required to use child-resistant packaging, ensuring they are not appealing to minors.
Summary
Senate Bill 682, introduced in the 2025-2026 legislative session, seeks to regulate hemp-derived cannabinoid products in Wisconsin. It includes significant amendments to existing statutes governing the definition of hemp and introduces a detailed regulatory framework for products derived from hemp. Notably, the bill defines 'hemp-derived cannabinoid' to include various forms of THC and outlines that any product containing these cannabinoids must meet stringent requirements before being sold or marketed. This contemporary approach reflects an evolving understanding of hemp and its derivatives in the marketplace, aligning with broader trends in cannabinoid regulation across the United States.
Contention
While the bill aims to ensure consumer safety and product transparency, it could also incite debate about the freedoms of businesses engaged in the hemp industry. Proponents argue that rigorous testing and labeling will enhance consumer trust and safety in a burgeoning market. Conversely, opponents may raise concerns about the burdens placed on small producers and the potential consequences of regulation that could be perceived as excessive or prohibitive. Broader discussions may emerge regarding how such regulations might apply to future developments in cannabinoid consumption and whether additional restrictions could hinder innovation within the industry.